Thomas Hanke


Expert in Residence
Head of Academic Partnerships at Evotec. 

Since November 2013, Thomas is responsible for a portfolio of drug discovery projects in the areas of inflammation and immuno-oncology at Evotec. In addition, Thomas’ focus is on building high-value, performance based drug discovery alliances with academia and pharma. From 2007 to 2013, Thomas was Sourcing Director at the Biopharm. Research Unit of Novo Nordisk, where he identified and evaluated partnering opportunities related to compounds, targets and technologies within haemophilia, autoimmune/inflammatory diseases, growth disorders and protein technologies and where he initiated multiple agreements with academic institutions and biotech companies both in Europe and in the US.

Prior to joining Novo Nordisk, Thomas was co-founder and Chief Scientific Officer at TeGenero, a German biotech company where he headed the R&D efforts to develop first-in-class immunomodulatory monoclonal antibodies (2002-2007). Preceding his entrepreneurial activities, Thomas was group leader and Assistant Professor for Immunobiology at the University of Würzburg (1999-2002) following a PostDoc at the University of California in Berkeley where he researched basic cellular immunology (1996-1999). Thomas received his Ph.D. in Biology from the University of Würzburg in 1995.

He is (co-) author of approx. 30 scientific papers in peer-reviewed journals. Thomas particularly likes to work in cross-functional teams, setting directions and fostering innovation and continuous improvement.

Dr Carlolyn Porter


Deputy Head of Technology Transfer, Pharma and Biotech
Oxford University Innovation Ltd.

Since joining Oxford University Innovation in 2009 Carolyn has led or mentored the formation of 14 spin-out companies from Oxford University commercialising a diversity of innovative technologies addressing distinct challenges in healthcare. She sits on the board of 4 of these companies. 

Recent Oxford spin-outs include Vaccitech, Evox and Oxstem collectively raising £36.9M in seed financing. 

Prior to Oxford University Innovation, Carolyn worked in senior Business Development roles in Novartis and Chiron and in the Mergers and Acquisitions team at Ernst & Young.  Previously Carolyn held post doc positions at Oxford University in the fields of cell signalling and immunology. 

She has a first class honours degree in Pharmacology from University College Dublin, a PhD in Immunology from Trinity College Dublin and an MBA from Warwick University

Andrew McLean


Life Sciences Head at Oxford Sciences Innovation.

Andrew joined OSI from McKinsey & Co. At McKinsey he was deeply embedded in both the private equity and pharmaceuticals practices. He is a physician with training in orthopaedic surgery who also completed a degree in philosophy, politics and economics at Christ Church, Oxford. He cut his investing teeth on the trading floor at Goldman Sachs.

John Davis


John is a biochemist by training with a PhD from the University of Cambridge. 

Following postdoctoral training at the Ludwig Institute (Middlesex) and the Salk Institute, John joined GlaxoSmithKline where he led a variety of non-clinical pharmacology research departments for pain and neurodegenerative diseases. In 2010, John and colleagues formed the spinout company Convergence Pharmaceuticals which was later acquired by Biogen. John was Director of Discovery for Selcia Ltd. and a cofounder of Cypralis Ltd. before joining the University of Oxford to lead the Alzheimer’s Research UK Oxford Drug Discovery Institute in 2015.

John has 20+ years of drug discovery expertise from target to phase IIa and has helped steer a dozen drug candidates into clinical development and to four positive proof of concepts.